Gardiquimod trifluoroacetate

• CAT Number: I012953
• CAS Number: 1159840-61-5
• Molecular Formula: C₂₁H₂₅F₆N₅O₅
• Molecular Weight: 541.44
• Purity: ≥95%
• Target: Toll-like Receptor (TLR)HIV
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IUPAC Name: 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C17H23N5O.2C2HF3O2/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18;2*3-2(4,5)1(6)7/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20);2*(H,6,7)
• InChIKey: XFQPQSJDMJVOBN-UHFFFAOYSA-N
• SMILES: CCNCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O

Gardiquimod trifluoroacetate（Cat No.:I012953） is a trifluoroacetate salt of Gardiquimod, a selective agonist of Toll-like receptor 7 (TLR7). It activates TLR7-mediated immune responses, leading to the production of cytokines and induction of an antiviral state. Additionally, Gardiquimod trifluoroacetate has been shown to exhibit inhibitory effects on HIV-1 reverse transcriptase, an enzyme critical for the replication of the virus. This dual activity suggests its potential use in the treatment of viral infections, including HIV-1.

Reference

[1]. Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18.[2]. Ma F, et al. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010 Sep;7(5):381-8.